Aspen Aerogels stock
ASPNNYSEAspen Aerogels, Inc., Basic MaterialsISIN US04523Y1055
45Score 45 out of 100, Weak
Price and trend
90 / 100
Price history
+75% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 26% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 13% below its 52-week high. Largest decline in 12 years: 96% (November 2021 to February 2026).
Chart figures for advanced users
- SMA 50$5.32
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.57
- The lowest closing price of the last twelve months.
- Resistance$6.89
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Aspen Aerogels, Inc. belongs to the Chemicals (Specialty) industry (United States) and, with a market value of $497.94M, is number 98 of 106 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $271.1M (down 40.1% year on year) and a loss of $389.55M.
- For fiscal 2026, analysts expect on average revenue of $224.73M (down 17.1%) and adjusted earnings per share of −$0.75.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 358 of 461 in Basic Materials, median 57.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 22% a year since 2020, Chemicals (Specialty) median 6%.Growth 64
- More cash than debtCash $145.99M, financial debt $104.87M.
Weaknesses
- DilutionShare count up 213% since 2020.Capital allocation 18
- Loss-makingLoss of $130.29M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 91% a year over the last 12 months.Stability 47
Its standout strengths are technical analysis and momentum, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 39.3% on the twelve months before. Revenue has grown strongly since 2009, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 17%, operating −19%, net −144%. Last 12 months: net −61%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 5 Nov 2026EPS reported $0.11 (expected −$0.09)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.750.0%
- Revenue
- $224.73M0.0%
- Earnings per share
- −$0.180.0%
- Revenue
- $280.37M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +22.3%Second quarter revenue expected at $40 million to $48 million, higher than in the first quarter; the company gave no comparison to earlier guidance.
“For the second quarter of 2026, we expect increased revenue and profitability relative to Q1, with total revenue expected to be between $40 million and $48 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $58.09M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Wood River Capital, LLCSale
23 Sept 2026, Major holder
- Shares
- 12,280,426
- Price
- $4.73
- Value
- $58.09M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Aspen Aerogels
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
461 rated companies in Basic Materials
- This company
- 45
- Sector median
- 57
Categories against the sector medianMedian of 461 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- EPC GroupeEXPL.PA $694.55M57
- Mativ HoldingsMATV $662.86M55
- Koppers HoldingsKOP $595.85M41
- Lightwave LogicLWLG $522.63M29
- Plastika KritisPLAKR.AT $461.15M67
- GevoGEVO $460.12M43
- AdvanSixASIX $425.12M42
- Uzin UtzUZU.DE $372.27M57
ETFs that hold Aspen Aerogels
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.03% | 0.39% | €1.49B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.